文献速递乳腺外科

接受乳房切除联合即刻重建的导管原位癌患者腋窝手术降阶梯:常规前哨淋巴结活检是否过度治疗?

De-escalating axillary surgery in ductal carcinoma in situ undergoing mastectomy with immediate reconstruction: Is routine sentinel lymph node biopsy an overtreatment?
PubMed 文献 · Surgery · 2026-05-12

该单中心回顾性研究纳入2014至2024年188例术前诊断为导管原位癌并接受乳房切除联合即刻假体重建的患者,所有患者均行前哨淋巴结活检。49例(26.1%)升级为浸润性癌,13例(6.9%)发现前哨淋巴结转移(pN1mi/pN1);多灶病变、存在浸润成分、组织学亚型和病理肿瘤大小与淋巴结阳性显著相关。结论提示基于术前危险因素选择性行前哨淋巴结活检可能安全省略,减少手术并发症。

要点

  • 术前导管原位癌行乳房切除加即刻重建者,前哨淋巴结转移率为6.9%。
  • 26.1%患者术后升级为浸润性癌,多灶病变和浸润成分与淋巴结阳性相关。
  • 基于术前危险因素选择性行前哨淋巴结活检可能安全省略,避免过度治疗。

核心结论

  • 对于接受乳房切除联合即刻重建的导管原位癌患者,常规前哨淋巴结活检可能并非必要。
  • 基于术前危险因素仔细选择患者,可安全省略前哨淋巴结活检,减少手术并发症而不影响肿瘤安全性。
  • 在此特定情况下,常规前哨淋巴结活检可能代表系统性过度治疗。

研究设计与样本

  • 单中心回顾性研究,纳入2014至2024年188例术前诊断为导管原位癌并接受乳房切除联合即刻假体重建的患者。
  • 分析临床病理特征、升级为浸润性癌的比例及前哨淋巴结状态,评估淋巴结受累与临床或病理变量的关联。

主要发现

  • 所有患者均行前哨淋巴结活检;49例(26.1%)升级为浸润性癌。
  • 13例(6.9%)发现前哨淋巴结转移(pN1mi/pN1)。
  • 多灶病变(P = .023)、存在浸润成分(P < .001)、组织学亚型(P < .001)和病理肿瘤大小(P < .0001)与淋巴结阳性显著相关。
  • 绝经状态、肿瘤分级、激素受体和人表皮生长因子受体2状态与淋巴结阳性无显著关联。

临床怎么用

  • 术前诊断为导管原位癌拟行乳房切除联合即刻重建时,可基于多灶病变、浸润成分、组织学亚型和病理肿瘤大小等危险因素选择性行前哨淋巴结活检。
  • 对无上述危险因素的患者,可考虑安全省略前哨淋巴结活检以减少手术并发症。

局限性

  • 单中心回顾性研究,样本量为188例,可能存在选择偏倚。
  • 研究仅纳入接受乳房切除联合即刻假体重建的患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ undergoing mastectomy remains controversial. Current guidelines recommend sentinel lymph node biopsy at the time of mastectomy because of concerns regarding occult invasive disease and the loss of lymphatic mapping after breast removal. However, axillary metastases are uncommon in ductal carcinoma in situ, and routine sentinel lymph node biopsy may represent overtreatment in selected patients. This study aimed to identify clinicopathologic factors associated with nodal positivity in order to support a selective approach to sentinel lymph node biopsy. METHODS: We retrospectively reviewed 188 consecutive patients with a preoperative diagnosis of ductal carcinoma in situ who underwent mastectomy with immediate implant-based reconstruction between 2014 and 2024 at a single institution. Clinicopathologic characteristics, rates of upstaging to invasive carcinoma, and sentinel lymph node status were analyzed. Associations between nodal involvement and clinical or pathologic variables were evaluated, and findings were compared with predictors identified in the literature. RESULTS: Sentinel lymph node biopsy was performed in all patients. Overall, 49 patients (26.1%) were upstaged to invasive carcinoma. Sentinel lymph node metastases (pN1mi/pN1) were identified in 13 patients (6.9%). Multifocal disease (P = .023), the presence of an invasive component (P < .001), histologic subtype (P < .001), and pathologic tumor size (P < .0001) were significantly associated with nodal positivity. No significant associations were observed with menopausal status, tumor grade, or hormone receptor and human epidermal growth factor receptor 2 status. CONCLUSION: Routine sentinel lymph node biopsy may not be necessary for all patients with ductal carcinoma in situ undergoing mastectomy with immediate reconstruction. Careful patient selection based on preoperative risk factors can allow safe omission of sentinel lymph node biopsy, reducing surgical morbidity without compromising oncologic safety. Our findings suggest that routine sentinel lymph node biopsy in this specific setting may represent systematic overtreatment.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Scardina L, D'Archi S, Accetta C, et al. De-escalating axillary surgery in ductal carcinoma in situ undergoing mastectomy with immediate reconstruction: Is routine sentinel lymph node biopsy an overtreatment? Surgery. 2026. PMID: 42208474. doi:10.1016/j.surg.2026.110314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。